Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics tags : Phase 3 save search
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -8.91%
zynlonta biopharma trial china phase 3
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell DiseasePhase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
Published: 2022-06-29 (Crawled : 13:20) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.34%
H: 10.15%
C: 8.54%
gbt601 trial phase 3
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
Published: 2022-06-27 (Crawled : 13:20) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.64%
H: 29.84%
C: 15.32%
treatment trial therapeutics phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -1.36%
H: 2.53%
C: 0.0%
trials therapeutics presentation sclerosis phase 3
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
Published: 2022-06-22 (Crawled : 13:00) - biospace.com/
VTGN | $4.77 1.49% 1.47% 150K
|
Health Technology
|
| O: 5.37%
H: 1.85%
C: -5.56%
ph94 treatment social anxiety disorder phase 3
G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: -12.68%
H: 0.0%
C: -6.91%
trilaciclib trial therapeutics cancer phase 3
Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress
Published: 2022-06-10 (Crawled : 13:20) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -5.67%
H: 0.0%
C: 0.0%
therapeutics phase 3
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 21.45%
H: 0.0%
C: 0.0%
drug disease eye application trial therapeutics phase 3
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
Published: 2022-06-07 (Crawled : 21:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.25%
H: 0.0%
C: 0.0%
conference disease eye trial therapeutics results topline phase 3
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-06-03 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 5.63%
H: 11.62%
C: 6.54%
trials therapeutics presentation sclerosis phase 3 multiple sclerosis
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
Published: 2022-06-01 (Crawled : 12:00) - biospace.com/
SAGE | $13.35 2.42% 2.36% 1.3M
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -1.11%
H: 0.11%
C: -0.99%
therapeutics depression phase 3
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical PsychiatryAXS-05
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
Analysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
Published: 2022-05-31 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 3.63%
H: 0.53%
C: -5.48%
uplizna genetic phase 3
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
Published: 2022-05-31 (Crawled : 12:00) - globenewswire.com
AXSM | $67.91 3.33% 3.22% 890K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
Published: 2022-05-26 (Crawled : 12:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.81%
H: 5.31%
C: 1.2%
trials therapeutics sclerosis phase 3 multiple sclerosis
SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -2.45%
H: 2.51%
C: -10.09%
trial therapeutics phase 3
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -4.95%
disease test eye trial therapeutics designation phase 3 reproxalap
Aldeyra Therapeutics Announces that Post-Hoc Analysis of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
Published: 2022-05-18 (Crawled : 13:00) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 2.14%
H: 0.0%
C: -6.11%
ocular trial therapeutics phase 3 reproxalap
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: 1.71%
H: 1.69%
C: -0.56%
conference trial therapeutics phase 3
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome PatientsPhase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
Published: 2022-05-09 (Crawled : 13:00) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.83%
H: 0.97%
C: -9.22%
fda expected trial therapeutics phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.